Advertisement

Picture EBD Group Connector Personal Networking in Life Sciences 650x80
Document › Details

Depixus S.A.S.. (3/22/21). "Press Release: Depixus Announces Peer-reviewed Publication Describing the Detection of Sequence Variation and Base Modifications on DNA and RNA Using Its Novel MAGNA Technology". Paris & Cambridge.

Organisations Organisation Depixus S.A.S.
  Group Depixus (Group)
  Organisation 2 Optimum Strategic Communications
Products Product MAGNA™ technology (Depixus)
  Product 2 genomics
Persons Person Hamilton, Gordon (Depixus 202112 CEO + Co-Founder)
  Person 2 Mathur, Supriya (Optimum Strategic Communications 201905 before Hume Brophy)
     


- Novel technology expected to greatly advance the burgeoning field of dynamic genomics

- Wide range of possible translational and clinical applications, including virology and epigenetic biomarker discovery for liquid biopsy tests


Depixus®, a biotechnology company developing a unique platform technology for the fast, accurate, and inexpensive extraction of multiomic information from DNA, RNA, and protein, today announces the publication of a scientific paper in the peer-reviewed journal Communications Biology, part of Nature Research journals. The paper, entitled 'Detection of genetic variation and base modi?cations at base-pair resolution on both DNA and RNA', can be freely downloaded from https://doi.org/10.1038/s42003-021-01648-7.

Dr. Gordon Hamilton, co-founder and Chief Executive Officer of Depixus, said: "Our novel technology, known as MAGNA™, can decode many new layers of dynamic genetic information held within DNA, RNA, and proteins. These information layers – that can be collectively described as the 'dynamic genome' – include the multitude of base modifications that pattern both DNA and RNA, as well as the many ways in which these nucleic acids can be constructed, folded, and packaged within cells. In this paper, we are excited to be publishing data that demonstrates how our MAGNA™ platform can sequence a wide range of base modifications on long molecules of both DNA and RNA with very high accuracy and without need for sample amplification. We also provide an example of how the technology, when applied to analysis of genetic disease from DNA coming from a female carrier of Fragile X Syndrome, can reveal the extent of the genetic and epigenetic perturbations that are associated with disease severity.

"Progress in decoding the dynamic genome is currently hampered by the lack of robust tools. The MAGNA™ platform was purpose-designed to resolve this problem and is being developed to allow researchers to open up new areas of genetic science, in particular in the burgeoning fields of epigenomics and epitranscriptomics. The data provided by MAGNA™ will help in better understanding the genomics of biological systems and will provide new insights into the pathogenesis of disease. The current coronavirus pandemic has highlighted the need for a much deeper understanding of the role that RNA base modifications play in virus-host interactions. The analysis of base modification patterning on DNA is already transforming the field of liquid-biopsy for early cancer detection."

Epigenetics refers to a "heritable" phenomenon in which phenotype changes are driven by processes that are independent of DNA sequence. DNA base modifications play central roles in such epigenetic processes. Epitranscriptomics, a new but fast-growing field, is the study of the enormous number of chemical modifications to RNA, and the proteins that write, erase, and read these modifications. In recent years, reversible modifications on nucleic acids (DNA and RNA) have been shown to play essential roles in many biological processes in health and disease.

Depixus is developing its MAGNA™ technology for future commercial launch. The company is based in Paris, France and Cambridge, UK, and over 2021 will be actively recruiting top talent to join its team.


For further information, please contact:

Depixus®
Gordon Hamilton, CEO
gordon.hamilton@depixus.com

Optimum Strategic Communications
Supriya Mathur, Shabnam Bashir
depixus@optimumcomms.com
+44 (0) 203 922 0891


About Depixus® and MAGNA™

Depixus® is a fast-growing innovative biotechnology company based in Paris, France, and Cambridge, UK, developing its cutting-edge MAGNA™ technology to reveal the secrets of the dynamic genome. The technology is set to transform our understanding of how genetics is regulated and provide powerful new insights into the mechanisms of disease.

The MAGNA™ technology is based on an instrument system called a 'magnetic trap'. Samples of nucleic acid are captured within a flow cell and then can be analyzed at multiple levels of resolution. The following animation – available at https://vimeo.com/394930924 – introduces the way the MAGNA™ technology works and some of the many different assays that can be performed with the platform.

For further information, please visit www.depixus.com

   
Record changed: 2021-12-17

Advertisement

Picture EBD Group Connector Personal Networking in Life Sciences 650x80

More documents for Depixus (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group Connector Personal Networking in Life Sciences 650x80




» top